NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo. The company has submitted an application to the local regulatory agency and secured financing to support the study, which aims to evaluate the oral antiviral in response to the ongoing Ebola outbreak. Currently, no approved treatment or vaccine exists for the Bundibugyo strain, highlighting the potential significance of this trial.
NV-387 is described by NanoViricides as the only orally administered Ebola treatment candidate under consideration for clinical testing. The company believes its broad-spectrum antiviral mechanism could offer advantages over infusion-based therapies, particularly in resource-limited outbreak settings where oral administration is more practical. NanoViricides noted that sufficient quantities of the drug are already in the DRC to support the planned study, pending regulatory approval.
The company’s novel nanoviricide technology is based on intellectual property and proprietary know-how licensed from TheraCour Pharma, Inc. NanoViricides focuses on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for respiratory viral infections such as RSV, COVID-19, and influenza, as well as for MPOX, smallpox, and measles. The company also has other drug candidates in development, including NV-HHV-1 for shingles and NV-CoV-2 and NV-CoV-2-R for COVID-19.
For leaders in business and technology, this announcement underscores the potential of novel antiviral platforms to address unmet medical needs in infectious disease outbreaks. The oral formulation could significantly impact outbreak management by simplifying logistics and reducing the need for intravenous administration, which is often challenging in remote or resource-constrained areas. If successful, NV-387 could set a precedent for oral antiviral treatments for Ebola and other viral hemorrhagic fevers.
The company’s development pipeline includes treatments for a wide range of viral diseases, such as HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, and coronaviruses. NanoViricides holds exclusive perpetual licenses to TheraCour’s nanomedicine technology for several human viral diseases. However, the company acknowledges the lengthy and capital-intensive nature of drug development, and there is no assurance that any of its candidates will prove effective or safe in clinical trials.
Investors and stakeholders can follow updates on NanoViricides in the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/t1kLC.
